Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dual specificity protein phosphatase 6 (DUSP6), also known as MKP-3, is an enzyme that specifically dephosphorylates the threonine and tyrosine residues of extracellular signal-regulated kinases 1 and 2 (ERK1/2) (UniProt, Q16828). By inactivating ERK, MKP-3 serves as a pivotal negative feedback regulator of the RAS/RAF/MEK/ERK signaling cascade, which is essential for regulating cell proliferation, differentiation, and apoptosis (Camps et al., 2000; PubMed PMID: 11042189). In the context of oncology, DUSP6 expression is often altered; it can function as a tumor suppressor in some tissues, while in others, such as pancreatic and lung cancer, its overexpression is linked to resistance against targeted therapies (Furukawa et al., 2003; PubMed PMID: 12692539). Beyond cancer, MKP-3 is involved in metabolic regulation, where its deficiency has been shown to protect against diet-induced obesity and insulin resistance (Wu et al., 2010; PubMed PMID: 20164305). Pharmacological targeting of MKP-3 has primarily focused on small-molecule inhibitors like BCI, which blocks its phosphatase activity and enhances ERK signaling (Molina et al., 2009; PubMed PMID: 19411067). These inhibitors are currently used as research tools to investigate the therapeutic potential of modulating MAPK signaling in various disease models.
Small molecule inhibition of the phosphatase catalytic domain or allosteric sites to prevent the dephosphorylation of ERK1/2, thereby modulating the duration and magnitude of MAPK signaling (Molina et al., 2009).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dual specificity protein phosphatase 6 (DUSP6) (MKP-3).